BigHat Biosciences

BigHat Biosciences is a biotechnology company based in San Mateo, California, founded in 2019. The company focuses on developing advanced antibody therapeutics through an AI-enabled platform that integrates machine learning, synthetic biology, and high-speed wet lab characterization. This innovative approach aims to accelerate antibody engineering, leading to safer and more effective treatments for challenging diseases. With a team of around 80 scientists and engineers, BigHat is dedicated to improving human health by simplifying the design of next-generation antibody therapeutics. The company has secured over $100 million in funding from 12 investors and operates primarily within the healthcare, pharmaceutical, and biopharmaceutical industries. BigHat is currently developing 10 therapeutics, including advanced antibodies for immuno-oncology and other protein-based therapies. The company has also formed a strategic collaboration with Johnson & Johnson Innovation to enhance its capabilities in antibody discovery and design.